Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

FGF-2 expression and its action in human leukemia and lymphoma cell lines

Leukemia volume 17, pages 818–820 (2003)Cite this article

TO THE EDITOR

Fibroblast growth factor-2 (FGF-2) is the prototypic member of the FGF family of growth factors. In the adult organism, FGF-2 coregulates a number of biological processes, including hematopoiesis. Recently, elevated FGF-2 levels in blood were reported in patients suffering from a number of hematopoietic malignancies, for example hairy cell leukemia, chronic myeloid leukemia, chronic lymphoid leukemia and non-Hodgkin's lymphoma.1,2,3 These findings suggest that a dysregulation of FGF-2 synthesis may be a common event in the development of hematopoietic neoplasm. There are at least three ways whereby FGF-2 could contribute to the pathogenesis of leukemia and lymphoma. First, FGF-2 is a potent activator of endothelial proliferation and can thus stimulate bone marrow angiogenesis. Second, FGF-2 promotes stromal fibroblast proliferation and extracellular matrix formation leading to excessive bone marrow fibrosis. Third, FGF-2 can directly affect neoplastic cells by acting on their high-affinity fibroblast growth factor receptors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R . Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood 1999; 94: 1077–1085.

    CAS  PubMed  Google Scholar 

  2. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245.

    CAS  PubMed  Google Scholar 

  3. Salven P, Teerenhovi L, Joensuu H . A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334–3339.

    CAS  PubMed  Google Scholar 

  4. Allouche M, Bayard F, Clamens S, Fillola G, Sie P, Amalric F . Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 1995; 9: 77–86.

    CAS  PubMed  Google Scholar 

  5. Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin DB . Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 1986; 129: 273–276.

    Article  CAS  Google Scholar 

  6. Delrieu I . The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett 2000; 468: 6–10.

    Article  CAS  Google Scholar 

  7. Van den Berghe L, Laurell H, Huez I, Zanibellato C, Prats H, Bugler B . FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2. Mol Endocrinol 2000; 14: 1709–1724.

    Article  CAS  Google Scholar 

  8. Tewari M, Yu M, Ross B, Dean C, Giordano A, Rubin R . AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Cancer Res 1997; 57: 4063–4069.

    CAS  Google Scholar 

Download references

Acknowledgements

We thank WR Wilcox for comments on the manuscript. This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (MSM432100001, LN00A065 and ME198) and the Academy of Sciences of the Czech Republic (AV0Z5039906).

Author information

Authors and Affiliations

  1. Laboratory of Molecular Embryology, Mendel University Brno, Brno, Czech Republic

    P Krejci, A Hampl & P Dvorak

  2. Department of Molecular Embryology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic

    J Faitova, A Hampl & P Dvorak

  3. INSERM U-531, Institut Louis Bugnard, Toulouse, France

    H Laurell

  4. Center for Cell Therapy and Tissue Repair, Charles University, Prague, Czech Republic

    A Hampl & P Dvorak

Authors
  1. P Krejci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Faitova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Laurell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Hampl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Dvorak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krejci, P., Faitova, J., Laurell, H. et al. FGF-2 expression and its action in human leukemia and lymphoma cell lines. Leukemia 17, 818–820 (2003). https://doi.org/10.1038/sj.leu.2402861

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402861

This article is cited by

Search

Advanced search

Quick links